Consistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the results of the Restore EF ...

AACHEN, Germany--(BUSINESS WIRE)--Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment ...

This screenshot from an Abiomed video demonstrates placement of the Impella 2.5 and Impella CP. Delivered in a minimally invasive way, Impella pumps actively unload the heart, aiding native heart ...

Randomized trials neutral for pump device in complex elective cases, STEMI with reperfusio ...

DANVERS, Mass. – Nov. 27, 2023 – Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).

Use of two high-risk cardiovascular devices—the Watchman (Boston Scientific) left atrial appendage occluder and the Impella (Abiomed) left ventricular assist device—is highest in the United States ...

Use of the Impella percutaneous left ventricular assist device (Abiomed) in acute MI complicated by cardiogenic shock (AMICS) in the United States increased nearly fivefold between 2012 and 2017, a ...

Abiomed, Inc. ABMD recently announced that it has successfully treated the first patient in Japan with Impella 5.5 with SmartAssist. The male patient on whom the procedure took place was treated for ...

For Abiomed’s beleaguered family of Impella heart pumps, Class I recalls are becoming a monthly event. The devices have racked up their third recall in as many months, the latest of which focuses on ...

The U.S. FDA posted notice of a medical device correction of Abiomed Inc.'s Impella series of left-side blood pumps because of the risk of perforation of the left ventricle during device placement.